CTAD 2024 | The development of lecanemab for the treatment of early Alzheimer’s disease

Lars Lannfelt, MD, PhD, Uppsala University, Uppsala, Sweden, provides a brief overview of the development of lecanemab for the treatment of early Alzheimer’s disease (AD). The discovery of an amyloid β (Aβ) precursor protein mutation as a potential therapeutic target in AD led to the inception of lecanemab. Promising data from the Phase II BAN2401-G000-201 (NCT01767311) and Phase III Clarity AD (NCT03887455) trials demonstrated the efficacy and safety of lecanemab, which led to the FDA approval of the drug in 2023. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.